1. Home
  2. RDI vs BOLD Comparison

RDI vs BOLD Comparison

Compare RDI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDI
  • BOLD
  • Stock Information
  • Founded
  • RDI 1937
  • BOLD 2018
  • Country
  • RDI United States
  • BOLD United States
  • Employees
  • RDI N/A
  • BOLD 64
  • Industry
  • RDI Movies/Entertainment
  • BOLD
  • Sector
  • RDI Consumer Discretionary
  • BOLD
  • Exchange
  • RDI Nasdaq
  • BOLD Nasdaq
  • Market Cap
  • RDI 30.6M
  • BOLD 24.4M
  • IPO Year
  • RDI N/A
  • BOLD 2024
  • Fundamental
  • Price
  • RDI $1.33
  • BOLD $1.17
  • Analyst Decision
  • RDI Hold
  • BOLD Buy
  • Analyst Count
  • RDI 1
  • BOLD 3
  • Target Price
  • RDI $2.40
  • BOLD $4.00
  • AVG Volume (30 Days)
  • RDI 32.9K
  • BOLD 283.9K
  • Earning Date
  • RDI 08-13-2025
  • BOLD 08-11-2025
  • Dividend Yield
  • RDI N/A
  • BOLD N/A
  • EPS Growth
  • RDI N/A
  • BOLD N/A
  • EPS
  • RDI N/A
  • BOLD N/A
  • Revenue
  • RDI $205,644,000.00
  • BOLD N/A
  • Revenue This Year
  • RDI $7.47
  • BOLD N/A
  • Revenue Next Year
  • RDI $13.22
  • BOLD N/A
  • P/E Ratio
  • RDI N/A
  • BOLD N/A
  • Revenue Growth
  • RDI N/A
  • BOLD N/A
  • 52 Week Low
  • RDI $1.17
  • BOLD $1.00
  • 52 Week High
  • RDI $1.89
  • BOLD $4.72
  • Technical
  • Relative Strength Index (RSI)
  • RDI 50.93
  • BOLD N/A
  • Support Level
  • RDI $1.24
  • BOLD N/A
  • Resistance Level
  • RDI $1.31
  • BOLD N/A
  • Average True Range (ATR)
  • RDI 0.06
  • BOLD 0.00
  • MACD
  • RDI -0.00
  • BOLD 0.00
  • Stochastic Oscillator
  • RDI 62.50
  • BOLD 0.00

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Share on Social Networks: